Long-term outcome of the Milano-hyperfractionated accelerated radiotherapy strategy for high-risk medulloblastoma, including the impact of molecular subtype.

Neuro Oncol · 2025 · PMC11726337 · PMID 39331528

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Subgrouping was performed in 66/89 patients and EFS showed a trend toward a poorer outcome for the 15 patients with SHH-tumors (2 with constitutional TP53 -mutations) versus patients with group 3 and 4 (#51) medulloblastoma (15-year EFS: 45.7%, 95% CI: 26.1%–80.2% vs 69.8%, 58.1%–83.9% CI: P = .065; Figure 4 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.